dn022150+ag (stage ii)
Pancreatic Carcinoma
Jiangxi Kvvit Pharmaceutical Co., Ltd.Phase 2/3Active
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
103 Active assets in the Pancreatic Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin OHSU Knight Cancer Institute | Phase 2/3 | BBB |
Irinotecan OHSU Knight Cancer Institute | Phase 2/3 | BBB |
FLUOROURACILUM Northwestern University | Phase 2/3 | BBB |
Gdc-0449 OHSU Knight Cancer Institute | Phase 2 | BB |
Capecitabine Zhejiang University | Phase 2 | BB |
View all 50 →
Same molecule, other indications
dn022150+ag (stage ii) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →